← Donald E. Cutlip

Papers by Donald E. Cutlip

Page 1 · newest first

1. The ISCHEMIA Trial a Decade Later—What Have We Learned?JAMA · 2026
2. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial InfarctionJournal of the American College of Cardiology · 2015
3. Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design PrinciplesJournal of the American College of Cardiology · 2015
4. Clinical Trial Principles and Endpoint Definitions for Paravalvular Leaks in Surgical ProsthesisJournal of the American College of Cardiology · 2017
5. Five-Year Follow-Up After Sirolimus-Eluting Stent ImplantationJournal of the American College of Cardiology · 2009
6. A Randomized Trial of a Dedicated Bifurcation Stent Versus Provisional Stenting in the Treatment of Coronary Bifurcation LesionsJournal of the American College of Cardiology · 2015
7. DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial InfarctionJournal of the American College of Cardiology · 2016
8. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting StentsJournal of the American College of Cardiology · 2018
9. Procedural Myocardial InfarctionJournal of the American College of Cardiology · 2020
10. Updated Standardized Endpoint Definitions for Transcatheter Aortic Valve ImplantationJournal of the American College of Cardiology · 2012
11. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical TrialsCirculation · 2014
12. Evaluation and Treatment of Patients With Lower Extremity Peripheral Artery DiseaseJournal of the American College of Cardiology · 2015
13. Type 2 diabetes in heart failure with preserved and mildly reduced ejection fraction: insights from the REDUCE-LAP-HF II trialESC Heart Failure · 2026
14. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical TrialsJournal of the American College of Cardiology · 2014
15. Heart Failure Duration, Cardiac Remodeling, Dysfunction, and Hemodynamic Severity in HFpEF and HFmrEFJACC Heart Failure · 2026
16. Trial Design Principles for Patients at High Bleeding Risk Undergoing PCIJournal of the American College of Cardiology · 2020
17. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical TrialsJournal of the American College of Cardiology · 2018
18. Standardized End Point Definitions for Clinical Trials in Thoracic Aortic Repair: A Consensus Report From the ARCH–Academic Research ConsortiumCirculation · 2026
19. Proposed Standardized Neurological Endpoints for Cardiovascular Clinical TrialsJournal of the American College of Cardiology · 2017
20. Proposed Standardized Neurological Endpoints for Cardiovascular Clinical TrialsEuropean Heart Journal · 2017
21. Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation Clinical TrialsJournal of the American College of Cardiology · 2011
22. Sirolimus-Eluting Balloon vs Repeat Drug-Eluting Stent or Balloon Angioplasty for Coronary In-Stent RestenosisJournal of the American College of Cardiology · 2026
23. Estimating the Placebo Effect on Patient-Reported Outcomes in Sham-Controlled Device Trials: Insights From REDUCE LAP-HF IICirculation Population Health and Outcomes · 2026
24. Definitions and standardized endpoints for the use of drug-coated balloon in coronary artery disease: consensus document of the Drug Coated Balloon Academic Research ConsortiumEuroIntervention · 2025
25. Underrepresented patient populations in cardiovascular device trials: A transatlantic expert narrative on sex, age, demographic groups, and geographical backgroundInternational Journal of Cardiology · 2025
26. Epicardial adipose tissue, functional status and invasive hemodynamics in heart failure with preserved ejection fraction.JACC Advances · 2025
27. Definitions and standardized endpoints for the use of drug-coated balloon in coronary artery disease: consensus document of the Drug Coated Balloon Academic Research ConsortiumEuropean Heart Journal · 2025
28. Long term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trialsAmerican Heart Journal · 2024
29. Drug-Coated Balloons in the Management of Coronary Artery DiseaseCirculation Cardiovascular Interventions · 2024
30. Defining high bleeding risk in patients undergoing transcatheter aortic valve implantation: a VARC-HBR consensus documentEuroIntervention · 2024
31. Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection FractionJAMA Cardiology · 2024
32. Obesity in Heart Failure with Preserved Ejection Fraction: Insights from the REDUCE LAP-HF II TrialEuropean Journal of Heart Failure · 2023
33. Standardized Definitions for Cardiogenic Shock Research and Mechanical Circulatory Support Devices: Scientific Expert Panel From the Shock Academic Research Consortium (SHARC)Circulation · 2023
34. Definitions and Standardized Endpoints for Treatment of Coronary BifurcationsJournal of the American College of Cardiology · 2022
35. Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor doseAmerican Heart Journal · 2021
36. Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus RecommendationsCirculation · 2021
37. Design and Rationale of a Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy (COBRA-REDUCE)Cardiovascular revascularization medicine · 2021
38. Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary RevascularizationJACC: Cardiovascular Interventions · 2020
39. Defining device success for percutaneous coronary intervention trials: a position statement from the European Association of Percutaneous Cardiovascular Interventions of the European Society of CardiologyEuroIntervention · 2020
40. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary InterventionCirculation · 2019
41. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding RiskEuropean Heart Journal · 2019
42. Periprocedural Stroke and Myocardial Infarction as Risks for Long-Term Mortality in CRESTCirculation Cardiovascular Quality and Outcomes · 2018
43. Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome PatientsCirculation Cardiovascular Interventions · 2018
44. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus DocumentCirculation · 2018
45. Standardized End Point Definitions for Coronary Intervention TrialsEuropean Heart Journal · 2018
46. Diabetes Drugs and Cardiovascular Event Reduction: A Paradigm ShiftUS Cardiology Review · 2018
47. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical TrialsCirculation · 2018
48. Factors associated with performing urgent coronary angiography in out‐of‐hospital cardiac arrest patientsCatheterization and Cardiovascular Interventions · 2017
49. Clinical Trial Principles and Endpoint Definitions for Paravalvular Leaks in Surgical ProsthesisEuropean Heart Journal · 2017
50. Cigarette smoking and cardio-renal events in patients with atherosclerotic renal artery stenosisPLoS ONE · 2017